Piper Sandler Upgrades Tvardi Therapeutics (NASDAQ:TVRD) to “Overweight”

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by equities research analysts at Piper Sandler from a “neutral” rating to an “overweight” rating in a research note issued to investors on Wednesday. The firm currently has a $13.00 target price on the stock. Piper Sandler’s price objective would suggest a potential upside of 166.61% from the company’s current price.

TVRD has been the subject of a number of other research reports. Raymond James Financial raised shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a research note on Wednesday. BTIG Research reissued a “buy” rating and issued a $15.00 price target on shares of Tvardi Therapeutics in a research report on Tuesday. UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price on the stock in a research note on Wednesday. HC Wainwright started coverage on shares of Tvardi Therapeutics in a report on Monday, June 8th. They issued a “buy” rating and a $9.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Friday, April 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Tvardi Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.29.

Tvardi Therapeutics Trading Up 57.3%

Shares of NASDAQ TVRD traded up $1.78 during midday trading on Wednesday, hitting $4.88. The company’s stock had a trading volume of 35,400,473 shares, compared to its average volume of 923,919. Tvardi Therapeutics has a 12-month low of $1.50 and a 12-month high of $43.65. The firm has a market cap of $45.74 million, a P/E ratio of -1.57 and a beta of 0.39. The business’s 50 day moving average is $3.05 and its two-hundred day moving average is $3.52.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.08). On average, analysts predict that Tvardi Therapeutics will post -2.39 earnings per share for the current fiscal year.

Institutional Trading of Tvardi Therapeutics

Several large investors have recently made changes to their positions in TVRD. Vanguard Group Inc. boosted its holdings in Tvardi Therapeutics by 5.2% in the third quarter. Vanguard Group Inc. now owns 419,167 shares of the company’s stock valued at $16,335,000 after purchasing an additional 20,757 shares during the last quarter. American Financial Group Inc. acquired a new position in shares of Tvardi Therapeutics in the 4th quarter valued at about $962,000. Vestal Point Capital LP purchased a new stake in shares of Tvardi Therapeutics in the third quarter worth about $6,508,000. Geode Capital Management LLC grew its holdings in Tvardi Therapeutics by 6.2% during the fourth quarter. Geode Capital Management LLC now owns 157,133 shares of the company’s stock worth $676,000 after acquiring an additional 9,214 shares during the period. Finally, State Street Corp raised its position in Tvardi Therapeutics by 83.7% during the fourth quarter. State Street Corp now owns 115,501 shares of the company’s stock valued at $497,000 after acquiring an additional 52,637 shares in the last quarter. 44.66% of the stock is owned by hedge funds and other institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.